Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.50 |
| ▸ | DDO | Q99489 | 1/20 | 0.50 |
| ▸ | KIF11 | P52732 | 3/20 | 0.44 |
| ▸ | DHFR | P00374 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | VDR | P11473 | 1/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24741123 | 0.81 | DAO (0.44) | DAODDOKIF11FLT3CYP1A2 | |
| SCHEMBL24371171 | 0.81 | DHFR (0.42) | DAOKIF11DHFRSLC2A1CYP1A2 | |
| SCHEMBL24447564 | 0.79 | RHEB (0.42) | KIF11DHFRSLC2A1FLT3ALDH1A1 | |
| SCHEMBL16380970 | 0.79 | DAO (0.49) | DAOKIF11DHFRSLC2A1FLT3 | |
| SCHEMBL16380895 | 0.79 | DHFR (0.48) | KIF11DHFRSLC2A1ALDH1A1HPGD | |
| SCHEMBL16380899 | 0.79 | DAO (0.49) | DAODDOKIF11DHFRSLC2A1 | |
| SCHEMBL24236481 | 0.77 | MEN1 (0.50) | DHFRSLC2A1FLT3MEN1MAPT | |
| SCHEMBL27017825 | 0.77 | DAO (0.55) | DAODDOKIF11DHFRSLC2A1 | |
| SCHEMBL21151024 | 0.77 | KIF11 (0.49) | KIF11DHFRSLC2A1CYP1A2CYP2C19 | |
| SCHEMBL27022285 | 0.77 | DHFR (0.39) | KIF11DHFRSLC2A1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303489-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2023-09-28 | — | — | US | disclosed |
| US-11708348-B2 | Protease inhibitors for treatment of coronavirus infections | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-07-25 | — | — | US | disclosed |
| US-20210040087-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-02-11 | — | — | US | disclosed |
| US-20170362180-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362180-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | DAO 297/4885DDO 873/4885KIF11 1469/4885 |
| US-20230303489-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | FUS, TFEB, CLN6 | DAO 4321/4885DDO 2857/4885KIF11 1125/4885 |
| US-20210040087-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | DAO 2163/4885DDO 2445/4885KIF11 4324/4885 |
| US-11708348-B2 | Protease inhibitors for treatment of coronavirus infections | ACE, ACE2, TMPRSS2 | DAO 328/4885DDO 150/4885KIF11 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.